Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fermented germinated brown rice
- Development stage
- Preclinical
- Lead developer
- Japanese company
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Fermented germinated brown rice (FGBR) is a functional food and dietary supplement candidate produced by fermenting germinated brown rice (GBR) with probiotic bacteria, specifically *Lactobacillus acidophilus*. It is being investigated for its potential chemopreventive effects against colorectal cancer (CRC). The fermentation process is thought to enhance the bioactive properties of GBR, leading to increased anti-inflammatory and pro-apoptotic activities. In preclinical models of colorectal carcinogenesis, FGBR has demonstrated the ability to reduce the formation of preneoplastic aberrant crypt foci (ACF) and sialomucin-producing ACF (SIM-ACF). Its mechanism of action involves the suppression of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β, and the modulation of apoptotic pathways by upregulating Bax and cleaved caspase-3 while downregulating the anti-apoptotic protein Bcl-2.
- Other names
- FGBRgerminated brown rice fermented by Lactobacillus acidophilus
02
Targets
IL-6 (Interleukin 6)TNFA (Tumor necrosis factor alpha (soluble))CASP3 (Caspase-3)IL1B (Interleukin-1 beta)BAX (Apoptosis regulator BAX)
Beyond the preview
Go deeper on fermented germinated brown rice.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fermented germinated brown rice.